ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Assessment of the optimal timing for projected dose evaluation in head and neck cancer patients treated with helical tomotherapy.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to determine the optimal time point at which the projected dose most accurately corresponds to the accumulated dose in head and neck cancer patients treated with helical tomotherapy. Dose metric differences between the International Commission on Radiation Units and Measurements Report 83 (ICRU83) (D50%) and Radiation Therapy Oncology Group (RTOG) (D95%) protocols were also evaluated for the planning target volume and critical organs, including the parotid glands, spinal cord, and brainstem. Materials and methods: This methods-oriented study analyzed data from 61 head and neck cancer patients treated with helical tomotherapy. It compared projected and accumulated doses across the treatment course, assessing dose discrepancies at fractions 1, 5, 10, 15, 20, 25, and 30. A ±3% threshold was defined as the acceptable deviation for both target volumes and critical organs. Results: Among the 61 patients analyzed, 70.5% had T3-T4 tumors and 68.8% were planned using the ICRU83 protocol. No deviations exceeding ±3% were observed in planning target volume dose 70 Gy (PTV70) (D50%) under ICRU83 protocol, whereas 35.0% of RTOG protocol (D95%) cases showed dose underestimation during fractions 1, 5, and 10. Deviations exceeding ±3% occurred most frequently in the left parotid gland (up to 75.4% of cases), followed by the right parotid gland, spinal cord and brainstem, particularly during early fractions. Conclusions: Projected dose proved to be a reliable metric for evaluating dose consistency, with D50% under ICRU83 protocol stable from early treatment and D95% under RTOG protocol consistent after fraction 15. However, variations in projected doses for organs at risk emphasize the need for cautious interpretation and individualized adaptive planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.